Why I’d buy shares in this growing, dividend-paying AIM company

This FTSE AIM All-Share Index (INDEXFTSE: AXX) company could be about to soar along with Boohoo Group plc (LON: BOO).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

When it comes to AIM (formerly known as the Alternative Investment Market), the opportunities to lose money are numerous. Thankfully for well-informed investors, the market does provide opportunities to invest in companies with huge growth potential. Often seeking out companies that already pay a dividend is a shortcut to finding the better stocks.

Abcam (LSE: ABC) is a great example of a successful and profitable AIM company. It provides the tools needed by life science researchers across the globe, and it’s a market leader in the field.

The company’s upward share price trajectory was recently abruptly reversed. Alongside results, it stated that its profit forecast for the new financial year will be “well below” expectations.

That’s always a catalyst for an immediate share price fall. Abcam was no exception. However, it may also provide a perfect entry point for picking up the stock at a cheaper price.

Providing the right ingredients for growth

Being a supplier to the life science market is a fundamentally attractive market to be in, with high margins, a global marketplace and significant barriers to entry. Abcam enjoys and profits from established relationships and reliance on its expertise to help researchers in the industry with their work.

The company has certainly made the most of its position within the market, and rewarded shareholders with a share price that had been rapidly climbing consistently for several years.

Despite the warning on expectations, the company’s results were actually pretty good and analysts have not rushed to downgrade the stock, which is a reassuring sign. The preliminary results for the year ended 30 June saw revenue up 7.4% on the previous year at £233.2m, EBITDA up 15.9% at £81.7m and profit before tax growing 33.1% to £69.1m.

As a dividend-paying AIM stock Abcam should continue to reward its investors, and already the share price is starting to recover from its recent plummet.

Another AIM success

Boohoo (LSE: BOO), the fast fashion retailer, is another AIM success story and has seen its share price rise even more quickly than Abcam’s since it listed on the stock exchange. This week the company announced the appointment of Primark’s chief operating officer, John Lyttle, for the role of chief executive. He’ll start in March 2019, which should boost growth and the share price in my opinion.

The latest results from Boohoo back in June saw it posting a 53% jump in first-quarter revenue. In the three months to the end of May, total group revenue rose to £183.6m from £120.1m the year before.

Investors will also have been buoyed by the strong performances from the group’s other brands, PrettyLittleThing and Nasty Gal. Their revenues grew by 158% and 149% to £79.2m and £7.2m, respectively.

When it comes to finding AIM stocks that will enhance your wealth, it can be tricky. Boohoo and Abcam, however, are both established companies with strong growth potential.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Andy Ross does not have a position in any of the companies mentioned in this article. The Motley Fool UK has recommended boohoo group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »